Search Results - "immunogenicity"

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial by Stephanie Pepin, Jean-François Nicolas, Henryk Szymanski, Isabel Leroux-Roels, Thomas Schaum, Marc Bonten, Giancarlo Icardi, Anju Shrestha, Cynthia Tabar, The QHD00011 study team

Connect to this object online.

Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial by Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Srikanth Adabala, Aditya Sri Javvadi, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Akshay Binayke, Aymaan Zaheer, Amit Awasthi, Chandramani Singh, Venkateshwar Rao A, Indranil Basu, Khobragade Akash Ashok Kumar, Anil Kumar Pandey

Connect to this object online.

Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults by Joon Young Song, Min Joo Choi, Ji Yun Noh, Won Suk Choi, Hee Jin Cheong, Seong-Heon Wie, Jin-Soo Lee, Gyu-Jin Woo, Sang Ho Lee, Woo Joo Kim

Connect to this object online.

Imunogenicidade da vacina contra hepatite B iniciada precocemente em pré-termos: implicações para a prevenção Immunogenicity of hepatitis B vaccination in preterm infants started soon after birth: the implications for prevention by Marisa M. Mussi-Pinhata

Connect to this object online.

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults by Sylvie Pichon, Francoise Guinet-Morlot, Jamshid Saleh, Brandon Essink, Andrea-Clemencia, Annick Moureau, Celine Petit, Ada-Maria Minutello

Connect to this object online.

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above by Jing Wang, FengJi Luo, ZiJian Feng, Li Li, YunHua Bai, Xing Ai, JianXin Ma, Zheng Zhang, NianMin Shi

Connect to this object online.

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa by Timo Vesikari, Luis Rivera, Tiina Korhonen, Anitta Ahonen, Brigitte Cheuvart, Marjan Hezareh, Winnie Janssens, Narcisa Mesaros

Connect to this object online.

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects by Yao F, Wang C, Ding J, Zhang Q, Zheng L, Zhang Q, Yang T, Zhang X, Shan Y, Hou S, Wang H, Zhou R, Hu W

Connect to this object online.

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU) by Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M. Sterling, Katrina M. Nolan, Gretchen M. Tamms, Luwy K. Musey, Ulrike K. Buchwald, for the V114-021 (PNEU-FLU)

Connect to this object online.

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India by Raches Ella, Radhika Bobba, Sanjay Muralidhar, Sudhir Babji, Krishna Mohan Vadrevu, Maharaj Kishan Bhan

Connect to this object online.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China by Shi-Yuan Wang, Shu-Zhen Liu, Kai Chu, Yue Zhao, Feng-Cai Zhu, Yue-Mei Hu, Fan-Yue Meng, Jing-Xin Li, Li Luo, Jia-Ying Yang, Pei Liu, Jun Yu

Connect to this object online.

Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults by Joon Young Song, Jacob Lee, Heung Jeong Woo, Seong-Heon Wie, Jin Soo Lee, Shin Woo Kim, Tae Hyong Kim, Sook-In Jung, Ji Yun Noh, Won Suk Choi, Hee Jin Cheong, Woo Joo Kim

Connect to this object online.

New Frontiers in Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases

Subjects: “…immunogenicity…”
DOAB: download the publication
DOAB: description of the publication

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life by Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas

Connect to this object online.

Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants by Krishna Kumari P, Siddharth Reddy Chiteti, Vinay K. Aileni, Sudhir Babji, William C. Blackwelder, Ashok Kumar, Jayant Vagha, Uma Nayak, Monjori Mitra, Narayanaappa D, Sonali Kar, Sangeeta Yadav, Swamy Naidu, Niranjan Mahantshetti, Vasant Khalatkar, Satyajit Mohapatra, P. K. Purthi, Pawan Sharma, A. Kannan, Ramchandra Keshav Dhongade, Sai D. Prasad, Raches Ella, Krishna Mohan Vadrevu

Connect to this object online.

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects by Yue Fei, Na Li, Weilin Qian, Yang Fan, Yu Shen, Quanren Wang, Kristi McLendon, Kai Shen

Connect to this object online.

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study by Franco M. Piazza, Miia Virta, Marita Paassilta, Benita Ukkonen, Anitta Ahonen, Alejandra Esteves-Jaramillo, Aino Forsten, Ilkka Seppa, Jian Ding, David Neveu, Emilia Jordanov, Mandeep S. Dhingra

Connect to this object online.

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material by Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen

Connect to this object online.

Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia by Dr. Ed Clarke, MBChB, Yauba Saidu, MD, Jane U Adetifa, MD, Ikechukwu Adigweme, MBBS, Mariama Badjie Hydara, MBBS, Adedapo O Bashorun, MBBS, Ngozi Moneke-Anyanwoke, MBBS, Ama Umesi, MBBS, Elishia Roberts, BSc, Pa Modou Cham, BSc, Michael E Okoye, MBBS, Kevin E Brown, MBBS, Prof. Matthias Niedrig, PhD, Panchali Roy Chowdhury, MSc, Ralf Clemens, MD, Ananda S Bandyopadhyay, MBBS, Jenny Mueller, MD, David J Jeffries, PhD, Prof. Beate Kampmann, MD

Connect to this object online.

A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months by Hitt Sharma, Sanjay Lalwani, Sameer Parekh, Pramod Pujari, Sunil Shewale, Sonali Palkar, Neeta Hanumante, Shilpa Gokhale, Jaganathan Ks, Rakesh Kumar, Inderjit Sharma, Sunil Gairola

Connect to this object online.